

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**
**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(37 CFR 1.98(b))

ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540794

APPLICANT: Dahl et al

FILING DATE: 1/13/2004

GROUP ART UNIT:

EXAMINER NAME:

Sheet 1 of 4

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AP		US - 4,724,233	02-09-1988	De Clercq et al	
		US - 4,808,716	02-28-1989	Holy et al.	
		US - 4,816,570	03-28-1989	Farquhar, David	
		US - 4,968,788	11-06-1990	Farquhar, David	
		US - 5,047,407	09-10-1991	Belleau et al.	
		US - 5,151,426	10-29-1992	Belleau et al.	
		US - 5,179,104	01-12-1993	Chu et al.	
		US - 5,204,466	04-20-1993	Liotta et al.	
		US - 5,210,085	05-11-1993	Liotta et al.	
		US - 5,466,806	11-14-1995	Belleau et al.	
		US - 5,486,520	01-23-1996	Belleau et al.	
		US - 5,538,975	07-23-1996	Dionne, Gervais	
		US - 5,587,480	12-24-1996	Belleau et al	
		US - 5,618,820	04-08-1997	Dionne, Gervais	
		US - 5,627,186	05-06-0197	Cameron et al.	
		US - 5,663,159	09-02-1997	Starrett, Jr. et al.	
		US - 5,696,254	12-09-1997	Mansour et al.	
		US - 5,733,788	03-31-1998	Bischofberger, Norbert	
		US - 5,744,596	04-28-1998	Mansour et al.	
		US - 5,756,706	05-26-1998	Mansour et al.	
		US - 5,763,606	06-09-1998	Mansour et al.	
		US - 5,792,756	08-11-1998	STARRETT JR. et al	
		US - 5,814,639	09-29-1998	Liotta et al.	
		US - 5,859,021	01-12-1999	Cameron et al.	
		US - 5,905,082	05-18-1999	Roberts et al.	
AP		US - 5,914,331	06-22-1999	Liotta et al.	
AP		US - 5,922,695	07-13-1999	Arimilli et al.	

/Alton Pryor/ (09/15/2006)

09/15/2006

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540794
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		APPLICANT: Dahl et al
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: 1/13/2004 GROUP ART UNIT:
(37 CFR 1.98(b))		EXAMINER NAME:
Sheet 2 of 4		

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AP		US - 5,935,946	08-10-1999	Munger, Jr. et al.	
		US - 5,977,089	11-02-1999	Arimilli et al	
		US - 6,043,230	03-28-00	Arimilli et al.	
		US - 6,057,305	05-02-00	Holy et al.	
		US - 6,069,249	05-30-00	Arimilli et al.	
		US - 6,113,920	09-05-00	Maye et al.	
AP		US - 6,114,343	09-05-00	Liotta et al.	
		US - 6,312,662	11-06-01	ERION et al	

FOREIGN PATENT DOCUMENTS					
Examiner Initial	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
AP		WO 00/25797	05-11-00	TRIANGLE PHARMACEUTICALS, INC.	
		WO 02/068058	09-06-02	TRIANGLE PHARMACEUTICALS, INC.	
		WO 02/070518 A1	09-12-02	TRIANGLE PHARMACEUTICALS, INC	
		WO 02/08241	01-31-02	GILEAD SCIENCES, INC	
AP		WO 91/19721	12-26-1991	Glazier, Arnold	
AP		WO 92/14743	09-03-1992	EMORY UNIVERSITY	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column-issue number(s), publisher, city and/or country where published.			T
AP		BLACKBURN ET AL., "DNA and RNA structure", pp.15-81, NUCLEIC ACIDS IN CHEMISTRY AND BIOLOGY, 1996			
AP		BUNDGAARD ET AL, "Design and Application of Prodrugs", pp.113-191, TEXTBOOK OF DRUG DESIGN AND DEVELOPMENT, 1991			

EXAMINER	/Alton Pryor/ (09/15/2006)	DATE CONSIDERED	09/15/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540794 APPLICANT: Dahl et al FILING DATE: 1/13/2004 GROUP ART UNIT: EXAMINER NAME:
---	--

Sheet 3 of 4

Examiner initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium,catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
AP		BENZARIA ET AL, "Synthesis, in Vitro Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derivatives of 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA) as Potential PMEA Prodrugs with Improved Oral Bioavailability", 39:4958-4965, J MED CHEM, 1996	
		DE LOMBAERT ET, "N-Phosphonomethyl Dipeptides and their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitor", 37:498-511, J MED CHEM, 1994	
		DE CLERCQ, ERIK, "New Anti-HIV Agents and Targets", 22(6):531-565, MEDICINAL RESEARCH REVIEWS, 2002	
		FARQUHAR ET AL, "Biologically Reversible Phosphate-Protective Groups", 72:324-325, J PHARM SCI, 1983	
		FASMAN ET AL, "", pp 385-394, PRACTICAL HANDBOOK OF BIOCHEM AND MOLEC BIOL, 1989	
		FELL ET AL, "", 20:657-659, J PHARM PHARMACOL, 1968	
		FREEMAN ET AL., "3 Prodrug Design for Phosphate and Phosphonates", 34:112-147, PROGRESS IN MEDICINAL CHEMISTRY, 1997	
		FUNG, HORATIO B., "Tenofovir Disoproxil Fumarate: A Nucleotide Reverse Transcriptase Inhibitor for the Treatment of HIV Infection", 24(10):1515-1548, CLINICAL THERAPEUTICS, 2002	
		GILEAD SCIENCES, INC., "Data Comparing Viread (R) and Emtriva (R) to Combivir (R) as Part of Combination HIV Therapy Published in New England Journal of Medicine", pg. 1-5, Press Release, 2006	
		GILEAD SCIENCES, INC., "U.S. FDA Approves Gilead Sciences' Emtriva A one-capsule, Once-Daily Medication For The Treatment of HIV", pg.3-7, Press Release, 2003	
		HOSTETLER ET AL, "Greatly Enhanced Inhibition of Human Immunodeficiency Virus Type 1 Replication in CEM and HT4-6C Cells by 3'-Deoxythymidine Diphosphate Dimyristoylglycerol, a Lipid Prodrug of 3' -Deoxythymidine", 36(9):2025-2029, ANTIMICRO AG & CHEMO, 1992	
		HOSTETLER ET AL., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides", 265(11):6112-6117, J BIOL CHEM, 1990	
		JONES ET AL., "Minireview: nucleotide prodrugs", 27:1-17, ANTIVIRAL RES, 1995	
		KHAMNEI ET AL, "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs", 39:4109-4115, J MED CHEM, 1996	
		KUCERA ET AL, "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation", 6:491-501, AIDS RES & HUM RETRO, 1990	
AP		LOVEDAY, C., "Nucleoside reverse transcriptase inhibitor resistance", 26:S10-S24, JAIDS, 2001	
AP		LIEBERMAN ET AL, "", 1:177-178, PHARMACEUTICAL DOSAGE FORMS, 1989	

<u>/Alton Pryor/ (09/15/2006)</u>	<u>09/15/2006</u>
EXAMINER	DATE CONSIDERED
<hr/> EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449		ATTY DOCKET NO.: 270.PFUS SERIAL NO.: 10/540794
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		APPLICANT: Dahl et al
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: 1/13/2004 GROUP ART UNIT:
(37 CFR 1.98(b))		EXAMINER NAME:
Sheet 4 of 4		

Examiner initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column-issue number(s), publisher, city and/or country where published.	T
AP		MULATO ET AL, "Anti-HIV Activity of Adefovir (PMEA) and PMPA In Combination With Antiretroviral Compounds: In Vitro Analyses", 36(2):91-97, ANTIVIRAL RES, 1997	
		MURRY ET AL, "Reversion of the M184V Mutation in Simian Immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine", 77(2):1120-1130, J VIROL, 2003	
		PALLELLA ET AL., "", 338:853-860, J MED CHEM, 1998	
		PUECH ET AL., "Intracellular delivery of nucleoside monophosphates through a reuctase-mediated activation process", 22:155-174, ANTIVIRAL RES, 1993	
		PIANTADOSI ET AL., "Synthesis and Evaluation of Novel Ether Lipd Nucleoside Conjugates for Anti-HIV-1 Activity", 34:1408-1414, J MED CHEM, 1991	
		RICHMAN, DOUGLAS, "The use of chemotherapy to supress replication of the human immunodeficiency virus(HIV) has transformed the face of AIDS in the developed world. Pronounced reductions in illness and death have been achieved and healthcare utilization has diminished. HIV", 410:995-1001, NATURE, 2001	
		RICHMAN, DOUGLAS D., "Antiretroviral activity of emtricitabline, a potent nucleoside reverse transcriptase inhibitor", 6:83-88, ANTIVIRAL THERAPY, 2001	
		RISTIG, MARIA B., "Tenofovir Disoproxil Fumarate Therapy for Chronic Hepatitis B in Human Immunodeficiency Virus/ Hepatitis B Virus - Coinfected Individuals for Whom Interferon- and Lamivudine Therapy Have Failed.", 186:1844-1847, JOURN OF INFECT DISEASE, 2002	
		SIDDQUI ET AL., "Design and Synthesis of Lipophilic Phosphoramidate D4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for In Vitro Activity and QSAR", 42(20):4122-4128, J MED CHEM, 1999	
		YENI ET AL, "Antiretroviral Treatment for Adult HIV Infection in 2002", 288(2):222-235, JAMA, 2002	
AP		YUAN ET AL, "Degradation Kinetics of Oxycarbonyloxymethyl Prodrugs of Phosphonates in Solution", 18(2):234-237, PHARM RES, 2001	
AP		WWW.PROJECTINFORM.ORG, "Anti-HIV Drug Updates- Three Drugs on the Near Horizon", 35:4-7, PI Perspective, 2003	

/Alton Pryor/ (09/15/2006)	09/15/2006
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	